Lily Zhang has been awarded the "Top 50 Female Investors in China's Private Equity Industry"
On the occasion of International Women's Day, congratulations to LILY ZHANG, founding managing partner of TTM Capital, for being named one of the "50 Best Female Investors in China's Private Equity Industry." This list was compiled by "China Bridge" based on Research Database and survey questionnaires, taking into account candidates' investment and fundraising performance, project exit capabilities, industry influence, and other indicators.
In 2021, under the shadow of the pandemic, the investment industry also faced an unprecedented dark moment. But we also witnessed a group of people: "They" are resilient, combining strength and gentleness, courageous and determined, showcasing their contributions and creativity in turning the tide in the face of crisis. "They" are full of passion, poised and graceful, strategizing and demonstrating balanced leadership skills, proactive decision-making courage, and boundless enthusiasm for exploring the future. "They" are vibrant, insightful about the world, and adept in human relationships, remaining calm in the face of tremendous changes in the era while staying true to their original intentions... "They" are growing into new stars in China's investment community, contributing to the development and prosperity of the investment sector.
On the occasion of International Women's Day, congratulations to LILY ZHANG, founding managing partner of TTM Capital, for being named one of the "50 Best Female Investors in China's Private Equity Industry." This list was compiled by "China Bridge" based on Research Database and survey questionnaires, taking into account candidates' investment and fundraising performance, project exit capabilities, industry influence, and other indicators.
LILY ZHANG is the founding managing partner of TTM Capital, focusing on investments in biomedicine, medical devices, diagnostic reagents, and biotechnology. She previously served as a partner in the healthcare sector at DCM, with nearly 15 years of experience in multinational mergers and acquisitions, technology transfer, patent licensing, and extensive domestic and international investment experience in the life sciences field. She has successfully led investments in several biotechnology companies, including TJ Biopharma, Chengdu HitGen, Habour Biomed, Elpiscience, MXB Biotechnologies, Thousand Oak Biologics, and XinThera.
LILY ZHANG obtained her Master of Business Administration degree from the Wharton School of the University of Pennsylvania and is a doctoral student at the School of Life Sciences of Tongji University; she is a member of several life science industry associations, including The BayHelix Group, Sino-American Pharmaceutical Professionals Association (SAPA), China Pharmaceutical Innovation and Research Development Association (PhIRDA), the New Drug Investment Hundred-Person Circle, and the Wharton School Healthcare Club, as well as an industrial development advisor for Shanghai Lingang Economic Development (Group) Co., Ltd. (Lingang Group)
Regardless of identity and posture, hard working is the most beautiful color. Under the leadership of LILY ZHANG, TTM Capital has developed into a team of 16 people in just a year and a half, establishing offices in Shanghai and Suzhou. The team is deeply engaged in eight sub-sectors of the life sciences field and has scanned over 2,000 domestic and international projects. TTM Capital adheres to the original intention of "working together and helping each other," and keeps in mind the mission of "gathering talents to benefit the world and creating miracles." It is dedicated to discovering better investment opportunities, empowering invested companies, creating collaborative value, contributing to technological innovation in the life sciences field, and benefiting society.
About XinThera Pharmaceuticals, Inc
XinThera was established in 2021, based on a structural drug discovery platform, focusing on fast follow small molecule drug development for First-in-Class and blockbuster drugs. Since receiving seed round financing in February 2021, the company has rapidly developed its business. The company was co-founded by Dr. Qing Dong, former Chief Scientist at Hengrui Pharmaceuticals, and seasoned entrepreneurs who had successfully started four companies in the U.S. and built several NASDAQ-listed companies. The R&D team consists of senior oncology and immunology experts with over twenty years of experience in new drug development, having successfully developed seven marketed drugs and a dozen clinical candidates.
Who we are
TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies. TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.
